Detalhe da pesquisa
1.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Ann Hematol
; 103(1): 125-132, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731147
2.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
3.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582542
4.
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Lancet Oncol
; 16(16): 1617-29, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26596670
5.
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Blood
; 122(8): 1376-83, 2013 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775712
6.
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Br J Haematol
; 185(5): 944-947, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478966
7.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med
; 13(7): e7071, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558233
8.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet
; 376(9758): 2075-85, 2010 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21146205
9.
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Ann Hematol
; 89(2): 185-90, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19633847
10.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol
; 7(12): e861-e873, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242443
11.
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Ann Hematol
; 92(1): 121-3, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22820997
12.
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Clin Lymphoma Myeloma Leuk
; 18(8): 533-540, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29910180
13.
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Oncotarget
; 8(4): 5924-5935, 2017 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27779105
14.
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Anticancer Res
; 36(3): 1059-65, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26976998
15.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer J
; 11(12): 197, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34876566
16.
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Blood Cancer J
; 10(5): 58, 2020 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424154
17.
Ovarian hyperstimulation syndrome in systemic amyloidosis.
Amyloid
; 21(1): 69-70, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24433119
18.
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
J Clin Oncol
; 29(8): 986-93, 2011 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21282540
19.
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
J Clin Oncol
; 28(5): 800-7, 2010 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20048187
20.
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Blood
; 109(7): 2767-72, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17148584